-
H.C. Wainwright Initiates Radius Health At Buy, $55 Target
Monday, May 23, 2016 - 10:11am | 202Read More...H.C. Wainwright & Co.'s Carol Ann Werther initiated Radius Health Inc (NASDAQ: RDUS) at Buy with a $55.00 price target. The company's lead product candidate is abaloparatide (ABL), which is currently under review in Europe and the United States. "We expect launches in 4Q16 and 1Q17," said...
-
Analyst Says Viking Therapeutics Can Quadruple Because Of Its Relationship With Ligand Scientists
Thursday, April 7, 2016 - 2:35pm | 330Read More...Viking Therapeutics Inc (NASDAQ: VKTX) is up 87 percent on Thursday, trading at $2.66. The clinical-stage biopharmaceutical company was incorporated in 2012, and went public in 2015. At just shy of a year old, the metabolic/endocrine solutions company has seen some challenges, and is down 70...
-
Buy Ligand Shares; HC Wainwright Sets $146 Price Target
Thursday, March 3, 2016 - 10:04am | 243Read More...HC Wainwright initiated coverage of Ligand Pharmaceuticals Inc. (NASDAQ: LGND) with a Buy rating and 12 month price target of $146, saying Ligand is a profitable unique company that has royalty rights to over 140 potential medicines that its 85+ partners are funding the development. Analyst...
-
Ultragenyx Has Multiple Catalysts This Year, Says H.C. Wainwright
Tuesday, February 9, 2016 - 3:22pm | 591Read More...Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has multiple catalysts this year that could boost its stock price over $100 in the next 12 months. Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company working on the treatment of rare and ultra-rare diseases, with a focus on serious...
